CalciMedica, Inc. files 10-Q

CalciMedica reported a net income of $4.976 million for the three months ended March 31, 2026, a significant swing from a net loss of $5.042 million in the same period last year, primarily driven by a substantial non-cash gain from fair value adjustments to its warrant liability and promissory note. However, the company continues to face substantial doubt about its ability to continue as a going concern, with cash and cash equivalents projected to fund operations only into the fourth quarter of 2026, necessitating significant additional capital.